Home » News » 02/06 » AstraZeneca appeals in patents case

AstraZeneca appeals in patents case

Date published: 17/02/2006

AstraZeneca has lodged its appeal over losing the patent for hypertension treatment Toprol XL (metoprolol succinate). In January US court ruled that two patents for the extended release tablet were invalid and unenforceable finding in favour of the defendants KV Pharmaceutical, Andrx Corp and Novartis's Eon Labs.

The Toprol patent was due to expire in September 2007 and last year US sales for the drug hit $1,291 million. AstraZeneca continues to maintain that both patents are valid and enforceable. The threat of losing patents for anti-ulcerant Nexium and schizophrenia treatment Seroquel is also looming for AstraZeneca, although no court dates have been fixed.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.